ARCHIVES

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

R01 and P01 Grants Will No Longer Support Phase III Clinical Trials

July 25, 2013

Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol

March 5, 1999

House Passes Bill Authorizing NIH Funds; Veto Likely

August 2, 1991

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

March 19, 1999

Subcommittee chairman Critical Of DCR For Lack Of “Game Plan”

October 28, 1977

Comments Invited On Centers Program

November 27, 1987